Evaluation of RNase Therapy in Systemic Lupus Erythematosus: A Randomised Phase 2a Clinical Trial of RSLV-132

Lupus Sci Med. 2024;11:e001113 DOI 10.1136/lupus-2023-001113

Treatment with RSLV-132 was associated with lower rates of SAEs than placebo, although RSLV-132 therapy was not associated with a significant improvement in the mean CLASI score relative to placebo. However, results suggest that further evaluations of RSLV-132 in SLE should be undertaken with patients with more active disease who are most likely to benefit from RNase therapy.

The aim of this Phase two trial was to test the hypothesis that digestion of extracellular RNA may be of clinical benefit to patients with SLE.